HYPERTROPHIC CARDIOMYOPATHY

This study looked at the long-term safety of the drug mavacamten in adults with hypertrophic cardiomyopathy, a condition where the heart muscle thickens. About 314 people who had already finished earlier studies took part. The goal was to track side effects over time, not to cure…

This study tested whether the drug trientine can reduce heart muscle thickening and improve exercise ability in people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes abnormally thick. 154 adults with HCM took either trientine or a placebo for 1…

This study tested a new MRI technique using a contrast agent called mangafodipir to measure how well heart cells take up manganese, which reflects cell function. It included 44 participants: healthy volunteers and people with heart failure with preserved ejection fraction caused …

This phase 2 trial tested a drug called BX1514M in 38 people with hypertrophic cardiomyopathy, a genetic heart condition that can cause shortness of breath, chest pain, and dizziness. The drug aims to improve blood flow by tightening veins, which may reduce blockages in the heart…

This study looks at how inherited heart rhythm problems (like Long QT Syndrome) and heart muscle diseases (like Hypertrophic Cardiomyopathy) affect the quality of life and physical activity of children aged 6 to 18. Researchers will compare 107 children with these conditions to 1…

This study reviewed information from 683 adults with obstructive hypertrophic cardiomyopathy who took mavacamten through a support program in Canada. Researchers looked at patient characteristics and how long they stayed on the medication. The goal was to understand real-world us…

This study looked at how blood vessel function relates to heart blockage in people with a genetic heart condition called hypertrophic cardiomyopathy. Researchers measured blood flow and vessel flexibility in 40 adults. The goal was to understand the connection, not to test a trea…

This study collected information from over 15,000 people hospitalized with cardiomyopathy, a heart muscle disease. Researchers looked at how much these hospital stays cost and what the money was spent on. The goal was to understand the real-world financial impact and help manage …

This study tested whether a special PET imaging probe called [68Ga]CBP8 can measure scarring (fibrosis) in the hearts of people with cardiac amyloidosis, a rare condition where abnormal proteins build up in the heart. Researchers compared 18 participants with cardiac amyloidosis …

This pilot study enrolled 5 people with hypertrophic cardiomyopathy who needed an implantable cardioverter defibrillator (ICD) but did not require pacing. Participants were randomly assigned to receive either a subcutaneous ICD (placed under the skin) or a transvenous ICD (with l…

This early-phase trial tested a single oral dose of HRS-1893 in 20 healthy white male volunteers to see how the body processes the drug and whether it is safe. The study is a first step toward potentially treating hypertrophic cardiomyopathy, a condition where the heart muscle th…

This study looked for Fabry disease, a rare genetic disorder, in 409 Portuguese adults with unexplained heart muscle diseases. Researchers tested patients with different types of cardiomyopathy to see how many actually had Fabry disease. The goal was to better understand how comm…

This completed study looked at 258 people with different types of cardiomyopathy (a disease of the heart muscle) to see if special imaging could predict stroke risk. Researchers used echocardiograms and MRI scans to measure blood flow in the heart and check for silent brain infar…

This completed Phase 1 study looked at how HRS-1893 tablets are processed in people with mild or moderate kidney impairment compared to healthy subjects. The goal was to understand dosing needs for patients with hypertrophic cardiomyopathy who also have kidney issues. Twenty-four…